ArticleAmerican journal of translational research2021
Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Application and progress of the detection technologies in hepatocellular carcinoma.Genes & diseases · 2023Review
- Rare earth smart nanomaterials for bone tissue engineering and implantology: Advances, challenges, and prospects.Bioengineering & translational medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to probe into the diagnostic level and clinical value of ultrasound combined with enhanced MRI by Gd-BOPTA in hepatocellular carcinoma (HCC).
methodsA total of 58 suspected HCC patients in our hospital from January 2016 to November 2020 were collected as the research subjects, including 37 HCC and 21 non-HCC patients. The diagnostic results of ultrasound and enhanced MRI by Gd-BOPTA were compared, and the microvascular invasion in patients was assessed. The independent risk factors of microvascular invasion were analyzed by logistics regression, and the diagnostic value of these factors was tested by ROC.
resultsThe specificity, sensitivity and accuracy of enhanced MRI by Gd-BOPTA were 89.19%, 90.48% and 94.59%, respectively. The specificity, sensitivity and accuracy of ultrasound were 85.71%, 72.97% and 91.89%, and those of combined diagnosis were 76.19%, 97.30%, and 89.66%, respectively. The confirmation rate of microvascular invasion of enhanced MRI by Gd-BOPTA was dramatically higher than with ultrasound. Tumor diameter, comorbid cirrhosis and differentiation degree were independent risk factors of microvascular invasion, and ROC curve revealed that the area under the curve (AUC) of these risk factors was > 0.6.
conclusionEnhanced MRI by Gd-BOPTA combined with ultrasound has good diagnostic value in HCC patients, and it can be widely used in early HCC diagnosis and clinical examination.
Indexed as
Identifiers
34306478PMC8290690W3183524345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.